Xenoport, Inc.
USPTO PatentsView assignee record - 20 granted patents across 6 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Xenoport ranks #15,060 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 6 technology areas.
- #15,060
- of 49,997 US assignees by volume
- 28th percentile
- by Innovation Score (28.8/100)
- 15.9
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R15060 · US Corporation #15,060 · 20 grants
GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 20 grants
- MID-PACK #15,060/49,997
- PHOTO-FINISH Wellis USA
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 28.8/100
- CLAIMS-RICH 15.9 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Wellis USA Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Xenoport’s 28.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Xenoport
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Xenoport · this assignee 29
Xenoport · this assignee
29 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Xenoport's Innovation Score is 28.8/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Xenoport?
Each dot is one of Xenoport’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Xenoport’s own 15.9 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Xenoport's grants concentrate
Xenoport, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 90% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (8 grants) versus a trough of 3 in 2015. By volume, Xenoport sits between Wellis USA Inc. and Xtone, Inc..
Who files at Xenoport's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Wellis USA
Wellis USA Inc.
20 patents
- Werlatone
Werlatone, Inc.
20 patents
- Willow Garage
Willow Garage, LLC
20 patents
- Willow Laboratori…
Willow Laboratories, Inc.
20 patents
- Xi'an Novastar Te…
Xi'an Novastar Tech Co., Ltd.
20 patents
- Xjet
Xjet Ltd.
20 patents
- Xiros
Xiros Limited
20 patents
- Xtone
Xtone, Inc.
20 patents
- Xenoport ◀
Xenoport, Inc.
20 patents
What this shows Xenoport holds 20 patents at rank #15,053, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Xenoport
By rank, the assignees closest to #15,053 in granted patent volume.
- Wellis USA Inc. #15,049 · 20 patents
- Werlatone, Inc. #15,050 · 20 patents
- Willow Garage, LLC #15,051 · 20 patents
- Willow Laboratories, Inc. #15,052 · 20 patents
- Xi'an Novastar Tech Co., Ltd. #15,054 · 20 patents
- Xjet Ltd. #15,055 · 20 patents
- Xiros Limited #15,056 · 20 patents
- Xtone, Inc. #15,057 · 20 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Xenoport's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Xenoport's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 28th percentile higher than 28% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 15.0% |
| 2016 | 8 | 40.0% |
| 2017 | 4 | 20.0% |
| 2018 | 5 | 25.0% |
Which technologies does Xenoport, Inc. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Xenoport, Inc.'s patent record in context - here's where to go next.
- Xenoport, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 90% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #15,060 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Xenoport, Inc. against Wellis USA Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 28.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.